Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF and SS. Presented at the EORTC-CLTG Annual Meeting 2026, the findings represent one of the largest real-world evaluations of the therapy in Germany and add to evidence supporting its use in routine practice.

MINT was a company-sponsored, multi-centric, non-interventional real-world study across 18 centres. It assessed outcomes in a broad patient population, including clinically relevant subgroups such as LCT and fMF, and stratified by disease stage and MAR status.

MF and SS are forms of CTCL, a type of non-Hodgkin’s lymphoma that manifests on the skin. Symptoms can include persistent rashes, changes in skin colour and plaques or tumours. These visible symptoms can significantly affect patients’ quality of life.

Professor Chalid Assaf, Director of the Department of Dermatology and Venereology, Helios Klinikum Krefeld, said: “For patients living with mycosis fungoides and Sézary syndrome, understanding how treatments perform outside the controlled setting of clinical trials is critically important.

“The final MINT results demonstrate meaningful clinical outcomes across a broad patient population treated in routine practice and highlight the value of collaborative real-world research in helping clinicians make informed treatment decisions.”

Atrogi has announced positive human data for ATR-258, its first-in-class oral
GRK2-biased β2-adrenergic modulator designed to improve muscle function and
body composition.

In an eight-week investigator-initiated study in 13 overweight or obese adults, the therapy was well tolerated and associated with an approximately 13% mean improvement in lower-extremity muscle power. Participants also saw statistically significant reductions in fat mass and increases in lean mass.

The open-label, single-arm trial, led by Professor Morten Hostrup, evaluated three ascending dose levels of ATR-258. Treatment resulted in a mean 1.1 kg reduction in fat mass and a 0.8 kg increase in lean mass. Atrogi said the profile highlights the therapy’s potential in metabolic and muscle-related diseases with high unmet need.

Professor Tore Bengtsson, Chief Scientific Officer and Founder of Atrogi, said: “These first clinical data give us important confidence that our approach is translating. To see fat loss alongside an increase in lean muscle mass and improvement in muscle function represents a truly differentiated profile, and is highly encouraging."

He added: “Beyond muscle-sparing weight loss, we believe this mechanism also warrants investigation in sarcopenia and rare diseases marked by substantial muscle loss and weakness.”

The findings build on a landmark Cell publication from 2025, which established Atrogi’s GRK2-biased signalling approach and detailed first-in-human safety data from a 69-subject phase 1 trial. The new results provide first human proof-of-mechanism.